Therapeutic strategies through nicotinic receptor or dimebon

Shigenobu Nakamura

Rakuwakai Kyoto Clinical Trial Center

Galantamin reacts to a low concentration of acetylcholine by binding at an allosteric site of nicotinic receptor.The drug is expected to show a novel effect on Alzheimer's disease. Investigations are now carried out to reveal the mechanism of dimebon to treat Alzheimer's disease. Although the phase II study on dimebon exhibited a more pronounced effect on Alzheimer's disease than other drugs used for Alzheimer's disease, the phase III connection study has failed to demonstrate a significant effect of dimebon over placebo.

Address correspondence to Dr.Shigenobu Nakamura, Rakuwakai Kyoto Clinical Trial Center(2 Chinjicho, Otowa, Yamashina-ku, Kyoto 607-8062, Japan)